Investigational drugs in early-stage clinical trials for autism spectrum disorder

@article{Hong2019InvestigationalDI,
  title={Investigational drugs in early-stage clinical trials for autism spectrum disorder},
  author={Michael P. Hong and C. Erickson},
  journal={Expert Opinion on Investigational Drugs},
  year={2019},
  volume={28},
  pages={709 - 718}
}
ABSTRACT Introduction: Pharmacologic interventions in Autism Spectrum Disorder (ASD) have historically focused on symptom-based approaches. However, a treatment for the core social deficits has remained unidentified. While a definitive theory for the cause of ASD is not yet known, recent advances in our understanding of ASD pathophysiology have opened the door for research on new pharmaceutical methods to target core symptomology. Areas covered: Herein, we review the novel pharmacologic… Expand
Methylphenidate in Autism Spectrum Disorder: A Long-Term Follow Up Naturalistic Study
Cortical Gray Matter Injury in Encephalopathy of Prematurity: Link to Neurodevelopmental Disorders
S0033291721000192jrv 1..14
Association of Peripheral Blood Levels of Cytokines With Autism Spectrum Disorder: A Meta-Analysis

References

SHOWING 1-10 OF 130 REFERENCES
Early Pharmacological Treatment of Autism: A Rationale for Developmental Treatment
The role of immune dysfunction in the pathophysiology of autism
Immune dysfunction in autism: A pathway to treatment
Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism
Reversal of autism-like behaviors and metabolism in adult mice with single-dose antipurinergic therapy
Efficacy of Fetal Stem Cell Transplantation in Autism Spectrum Disorders: An Open-Labeled Pilot Study
Clinical and neural effects of six-week administration of oxytocin on core symptoms of autism.
...
1
2
3
4
5
...